Valeant Pharmaceuticals et al v. Actavis Laboratories

Actavis markets a generic version of the brand-name medication Uceris. The brand-name company and the owner of its IP have sued for infringement of formulation patents that allegedly cover Uceris. The district court construed the patent claims, and under that construction Actavis’s product does not infringe. Goodwin argues in this brief that the district court’s claim construction should be affirmed.

Valeant Pharmaceuticals et al v. Actavis Laboratories

Download PDF